Financial overview
First quarter Q1 2023 Group
(figures in brackets only refer to March 2022 as the group was formed on 1 March 2022)
- Net sales amounted to 0.
- Other operating income amounted toKSEK 39 (1,298).
- The profit after tax amounted to kSEK –7,580 (-3,675)
- Earnings per share before and after dilution: SEK-0.03 (-0.02).
- Cash flow from current operations was kSEK -5,402 (3,225) TSEK.
- Cash and cash equivalents amounted to kSEK 43,740 (39,827) as of 31 March 2023.
Fourth quarter Q4 2022 Parent company
- Net sales amounted to 0 (0).
- Other operating income amounted to kSEK 1,059 (144).
- The profit after tax amounted to kSEK -1,318 (-2,554).
- Earnings per share before and after dilution: SEK -0,00 (-0,02).
- Cash flow from current operations was kSEK -6,032 (-2,382).
- Cash and cash equivalents amounted to kSEK 39,519 (33,560) as of 31 March 2023.
Significant events during the quarter
- Prolight’s subsidiary Psyros achieved all milestones for the second phase of the SBRI Healthcare grant, primarily by producing functional prototypes for the company’s unique digital immunoassay.
- Prolight’s subsidiary Psyros chose Integrated Technologies Limited (ITL) to design and develop the commercial instrument for the digital immunoassay, which will be based on the existing functional prototypes. This next step in product development is based on the prototypes internally developed at the subsidiary Psyros.
- Prolight announced that the development project in distributed testing reached a positive milestone with the transfer of two laboratory-based diagnostic tests to the platform. The test results from the project indicate that commercially available laboratory tests can be transferred to the PLD MicroFlex POC platform.
Significant events after the end of the period
- Prolight´s subsidiary Psyros submitted two priority patent applications covering various aspects of multiplexing capabilities to the Intellectual Property Office in Great Britain.
CEO comment
We have worked intensively during the first quarter of the year with our unique digital immunoassay. The platform could become the first digital, ultra-sensitive, portable POC platform for testing high-sensitive troponin and eventually for performing many other clinical tests in large indication areas.
During this quarter, we selected Integrated Technologies Limited (ITL) as a partner to develop the commercial instrument. The collaboration was entered into to ensure that the commercial instrument is state-of-the-art and compliant with all regulatory standards required for an in-vitro diagnostic product (IVD). ITL brings deep manufacturing knowledge and high expertise in optics and mechanical engineering. We are delighted with our choice of partner and have already started good cooperation.
This next step in product development is based on the fully functional research-level prototypes we have developed in-house. We currently have six prototypes that will be used to develop the reagent cartridge and to define the requirements for developing the commercial platform.
As for the internal pilot production of cartridges, it will start in May in our renovated and adapted premises.
A promising sign of the high level we maintain within the Company is the grant from SBRI Healthcare. The quarter saw the completion of phase two of the approximately £1 million grant received last year. The allocation was conditional on implementing certain milestones that have now been met or exceeded, including developing fully functional prototypes. The grant has accelerated the development of the digital immunoassay and is a great recognition.
During the quarter, we were also pleased that TTP reached a positive milestone in the development project in distributed testing for PLD MicroFlex; two laboratory-based diagnostic tests were transferred to the platform, indicating that the platform will be able to be used for commercially available laboratory tests. TTP is now working on identifying a suitable commercial partner to continue the development necessary to bring the technology to market. We follow their work with great interest.
After the end of the quarter, we submitted two priority patent applications covering different multiplex aspects to the Intellectual Property Office in the UK. Multiplex means detecting several different biomarkers at the same time on a single sample. The first application covers various aspects of multiplexing. By using our unique single molecule counting technology, multiplexing can be carried out in a single drop of blood on a sensor without needing to split the sample into separate areas. The second application uses a similar approach to allow the measurement of the same biomarker at both very low and very high concentrations simultaneously. The benefit of the unique technology is that the sample size remains extremely small, and that the sensor is easy to manufacture, yet also offering the ability to detect very low concentrations of biomarkers with high specificity.
Our subsidiary Psyros has already filed three patent applications for its unique digital immunoassay technology. The first application has passed the PCT phase and is now being pursued in different territories worldwide. The second and third applications are in the PCT phase. The two new patent applications will enter the PCT phase in 2024.
Overall, our pioneering product platform for digital immunoassay has enormous potential and, as a first step, we are very well positioned to bring a high-sensitive troponin assay to the market. The system is also very easily operated and has low production costs making it incredibly costeffective, just what the market demands. I look forward to reporting back to you.
Lund in May 2023
Ulf Bladin, CEO Prolight Diagnostics AB (publ.)
